



Sensitivity and specificity of indocyanine green near-infrared fluorescence imaging in detection of metastatic lymph nodes in colorectal cancer: Systematic review and meta-analysis

By

Sameh Hany Emile, M.Sc., M.D.

Lecturer of General and Colorectal Surgery

Colorectal Surgery Unit


Mansoura University, Faculty of Medicine


Egypt

Background

- ▶ Fluorescence-guided surgery (FGS) is an imaging technique used to detect fluorescently labelled structures during surgery.
- ▶ Indocyanine green (ICG) a cyanine dye commonly used in FGS.
- ▶ It binds tightly to plasma proteins and has a half-life of 150-180 seconds.
- ▶ The fluorescence spectrum of ICG is in the near infrared (NIR) region, hence the fluorescence system is called ICG-NIR fluorescence imaging

Flourescence-guided laparoscopic surgery for CRC





Mapping of sentinel LNs


- ▶ Detection and removal of metastatic LNs is an integral part of the radical treatment of CRC.
- ▶ Mapping of SLN can be achieved preoperatively via various imaging modalities or intraoperatively.
- ▶ SLN detection can lead to better staging of CRC and warrant the indication for adjuvant chemotherapy in some cases.
- ▶ Furthermore, SLN mapping helps recognize aberrant lymphatic patterns which may change the extent of radical lymphadenectomy



Methods

- ▶ Systematic literature search in PubMed/MEDLINE, Scopus, and Cochrane library according to PRISMA guidelines.
- ▶ Original articles in the English language that assessed the efficacy of ICG NIR fluorescence in the detection of SLN in CRC were included.
- ▶ We excluded animal studies, irrelevant articles, editorials, comments, reviews, and meta-analyses.
- ▶ Studies that did not report the technical details of ICG injection and/or NIR fluorescence technique were excluded

PRISMA flow chart



Results

- ▶ Twelve prospective case series were included in the review
- ▶ The study population comprised 248 patients of a mean age of 66.3 years.
- ▶ There were 129 (52%) males and 119 (48%) females with a mean BMI of 25.8 Kg/m².
- ▶ 58% of patients had an early stage (TNM I/II) CRC and 42% had stage III/IV CRC.
- ▶ The percentage of patients with early stage CRC varied among the studies from 30 to 100% (median = 41%)


Study Characteristics

Study	Period of the study	Country	No.	Age	BMI	Early stage (I/II) tumors	Location of the tumor
Watanabe et al ²¹	July 2013-Jan 2016	Japan	31	67.5	23.6	31 (100%)	Splenic flexure
Liberale et al ³⁴	NA	Belgium	12	62.8	Na	Na	Right & left colon, rectum
Liberale et al ³⁴	Sept 2013-Nov 2015	Belgium	20	70.5	26.3	6 (30%)	NA
Liberale et al ²⁴	NA	Belgium	2	59.5	Na	0	Right & left colon
Handgraaf et al ²⁵	NA	The Netherlands	5	69	Na	2 (40%)	Rectum
Nishigori et al ²⁶	March 2013-June 2014	Japan	21	65.2	Na	8 (38%)	Right & left colon, rectum, appendix
Noura et al ²⁷	Jan 2007-Dec 2007	Japan	25	58.4	Na	9 (36%)	Rectum
Van der pas et al ²⁸	NA	The Netherlands	14	75.5	25.1	Na	Na
Hirche et al ²⁹	N/A	Germany	26	67	28.4	11 (42.3%)	Right & left colon, rectum
Cahill et al ³⁰	NA	UK	18	66.4	29.1	10 (55.5%)	Right & left colon, rectum
Kusano et al ³¹	2004-2006	Japan	26	70	Na	Na	Right & left colon, rectum
Nagata et al ³²	July 2002-Dec 2004	Japan	48	63.9	22.5	37 (77%)	Right & left colon, rectum

Technical aspects



- ▶ The studies used ICG of different commercial names, with different concentrations (0.5, 2.5, 5 mg/mL) and doses (0.2-5 mL).
- ▶ Additionally, there were variations in the site of ICG injection (submucosal, subserosal, both submucosal and subserosal, and intravenous) and the timing of the injection (preoperative, intraoperative, or both pre- and intraoperative).
- ▶ Time elapsed between ICG injection and detection of fluorescent LNs by NIR light ranged between 5 min in one study, 10 min in two studies, 15 min in two studies, and 30 min in three studies .

Fluorescent Vs Pathologic Examination of LNs







Sensitivity and Specificity of ICG NIR

- ▶ The median **sensitivity** rate for ICG fluorescence in the detection of malignant lymph nodes was 73.7, the median **specificity** rate was 100% and the median **accuracy** rate was 75.7%.
- ▶ The pooled **sensitivity** was 71% (95%CI: 68.3-73.3) with $I^2 = 96.8\%$, $P < 0.0001$.
- ▶ The pooled **specificity** was 84.6% (95%CI: 83.2-86) with $I^2 = 96.5\%$, $P < 0.0001$.



Sensitivity, specificity, and accuracy of ICG NIR fluorescence according to dose, site, and time of injection of ICG

Variable	Number of studies	Median sensitivity (%) (range)	Median specificity (%) (range)	Median Accuracy (%) (range)
Dose				
0.5 mg/mL	1	57	100	60.5
2.5 mg/mL	4	84.8 (0-100)	72.5 (0-100)	82.1 (0-100)
5 mg/mL	5	55.7 (0-100)	100 (9.1-100)	75.7 (20-99)
0.25 mg/kg	2	89 (77.8-100)	87.7 (75.5-100)	88 (75.8-100)
Site of injection				
Subserosal	5	55.7 (0-82.3)	100 (0-100)	75.7 (0-99)
Submucosal	4	84.8 (0-100)	59.7 (9.1-100)	68.8 (20-100)
Combined subserosal & submucosal	1	100	100	100
Intravenous	2	89 (77.8-100)	87.7 (75.5-100)	88 (75.8-100)
Time of injection				
Preoperative	3	100 (0-100)	74.4 (9.1-100)	73.5 (20-100)
Intraoperative	8	67.4 (0-100)	100 (0-100)	80.2 (0-100)
Preoperative and intraoperative	1	69.7	45	64.2



Courtesy of Manish Chand, Ph.D., UCL, UK

Conclusions

- ▶ ICG NIR fluorescence is a safe and promising technique for detecting metastatic LNs in CRC.
- ▶ The overall sensitivity, specificity, and accuracy of this technique vary according to a multitude of technical factors.
- ▶ Optimization of ICG fluorescence SLN mapping requires further large, well-designed randomized trials comparing different techniques of ICG injection to reach valid conclusions about its ultimate clinical utility.

Sensitivity and specificity of indocyanine green near-infrared fluorescence imaging in detection of metastatic lymph nodes in colorectal cancer: Systematic review and meta-analysis

Sameh H. Emile MD, MSc, PhD¹  | Hossam Elfeki MD, MSc^{1,2} |
Mostafa Shalaby MD, MSc^{1,3} | Ahmad Sakr MD, MSc¹ |
Pierpaolo Sileri MD, PhD, MS, FACS³ | Søren Laurberg MD, DMSc² |
Steven D. Wexner MD, PhD (Hon), FACS, FRCS, FRCS (Ed)⁴

*Thank
you*

